Metabolic shares suspended

By Ruth Beran
Friday, 10 June, 2005

Melbourne based Metabolic Pharmaceuticals (ASX:MBP) has suspended its shares from the ASX's official quotation in the lead-up to an announcement.

This follows a trading halt on June 8, and a recent clarification by the company of a previously announced Phase IIb trial of its anti-obesity drug AOD9604 to determine optimal dosage.

Free meningococcal B vaccines coming to the NT

The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...

Mouth bacteria linked to increased head and neck cancer risk

More than a dozen bacterial species that live in people's mouths have been linked to a...

Life expectancy gains are slowing, study finds

Life expectancy at birth in the world's longest-living populations has increased by an...

Content from other channels on our network

Air-gapped networks give a false sense of security

BHP strengthens partnership with ABB

Seamless modular I/O integration

Coca-Cola invests nearly $100 million in Queensland manufacturing

Endress+Hauser receives IEC 62443‍-‍4‍-‍1 cybersecurity certification

Review proposes major health system changes

Private Health CEO Forum to tackle financial viability issues

Medline introduces Namic Ready Set Kits

Solventum innovations enabling better, smarter, safer healthcare

Lumia Care expands national network with SA acquisition

Pacific Automation: Automation Components and Solutions for Australia's Food Processing Industry

What's New in Palletising

Scooping Up Success: Sajani Cups and Cones Freezes Out Stock Issues with Fishbowl

Managing Food Safety Risk Efficiently with Data Automation

Introducing Tool-Free Mounting and Reduced Service Times with Bürkert's Direct Acting Service Valves